MIAMI, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for...
Expands Trial to 17 U.S. Sites and 25 Locations Initiation of All Anticipated U.S. Trial Sites Largely Completed HOUSTON, Aug. 22,...
Phase II Clinical Trial for Pancreatic Cancer Planned for Q2 2023 FREMONT, CA, Aug. 22, 2022 (GLOBE NEWSWIRE) -- via...
WALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present...
WALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the...
MALVERN, Pa., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute...
LBS-008 (aka Tinlarebant) is Belite Bio’s orally administered tablet for the treatment of Stargardt disease (STGD1) and Dry AMDA 2-year...
Dosed first patient in Phase I/II trial evaluating Allocetra™ combined with chemotherapy in patients with peritoneal metastases arising from solid...
BOSTON, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class...
Arcutis Cares provides ZORYVE™ (roflumilast) cream 0.3% at no cost for financially eligible individuals who are uninsured or have Medicaid...
SAN MATEO, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the...
World first study utilizing Somalogic SomaScan® assay# to assess up to 7,000 plasma proteins in Long COVID-19 patients has elucidated...
~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to...
Oral presentation will include data from the Phase 2 trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in...
SAN FRANCISCO, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve...
Results from Planned Interim Analysis Expected First Half 2023 Long COVID Afflicts More Than 30% of Patients Following Infection with...
A review decision by the European Medicines Agency (EMA) is expected in the second half of 2023 If approved, sparsentan...
Clinical Trial Shows Substantially Increased Bioavailability with Food and a Clean Safety and Pharmacologic ProfileCALGARY, Alberta, Aug. 22, 2022 (GLOBE...
Management team will host R&D day on Thursday, September 15, from 10am ET in New York City with Key Opinion...
ZUG, Switzerland, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to...